258 related articles for article (PubMed ID: 37390646)
1. Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus.
Liao D; Liu C; Chen S; Liu F; Li W; Shangguan D; Shi Y
Int Immunopharmacol; 2023 Sep; 122():110414. PubMed ID: 37390646
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
Hilder R; Tsai K; Quandt Z; Isaacs D; Drakaki A; Xing Y; In GK; Angell TE; Lechner MG
Front Endocrinol (Lausanne); 2023; 14():1242830. PubMed ID: 38027216
[TBL] [Abstract][Full Text] [Related]
3. Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice.
Cho YK; Jung CH
Diabetes Metab J; 2023 Nov; 47(6):757-766. PubMed ID: 37482654
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
Yao L; Jia G; Lu L; Bao Y; Ma W
Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
[TBL] [Abstract][Full Text] [Related]
5. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
6. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
7. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
Okiyama N; Tanaka R
Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes.
Chen X; Affinati AH; Lee Y; Turcu AF; Henry NL; Schiopu E; Qin A; Othus M; Clauw D; Ramnath N; Zhao L
Diabetes Care; 2022 May; 45(5):1170-1176. PubMed ID: 35238899
[TBL] [Abstract][Full Text] [Related]
9. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
[TBL] [Abstract][Full Text] [Related]
11. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and therapeutic approach to pulmonary infiltrates in cancer patients receiving immune checkpoint inhibitors.
Fernández-Ruiz M
Rev Esp Quimioter; 2022 Oct; 35 Suppl 3(Suppl 3):67-73. PubMed ID: 36285862
[TBL] [Abstract][Full Text] [Related]
13. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
Front Immunol; 2022; 13():804597. PubMed ID: 35432346
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
Chen CH; Yu HS; Yu S
Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
[TBL] [Abstract][Full Text] [Related]
15. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
Dora D; Bokhari SMZ; Aloss K; Takacs P; Desnoix JZ; Szklenárik G; Hurley PD; Lohinai Z
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769093
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
Song P; Zhang D; Cui X; Zhang L
Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
[TBL] [Abstract][Full Text] [Related]
17. Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know).
Ruggeri RM; Campennì A; Giuffrida G; Trimboli P; Giovanella L; Trimarchi F; Cannavò S
J Endocrinol Invest; 2019 Jul; 42(7):745-756. PubMed ID: 30471004
[TBL] [Abstract][Full Text] [Related]
18. Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors.
Teng YS; Yu S
Curr Oncol; 2023 Jul; 30(7):6805-6819. PubMed ID: 37504358
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous manifestations associated with immune checkpoint inhibitors.
Watanabe T; Yamaguchi Y
Front Immunol; 2023; 14():1071983. PubMed ID: 36891313
[TBL] [Abstract][Full Text] [Related]
20. [IMMUNE CHECKPOINT INHIBITOR-INDUCED DIABETES MELLITUS].
Fischer M; Amos S; Levy L; Pollack R
Harefuah; 2021 Oct; 160(10):657-662. PubMed ID: 34689435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]